Want to see HRGN full AI Analyst Report?
HRGN Stock Chart & Stats
$1.58
$0.07(2.66%)
At close: 4:00 PM EST
$1.58
$0.07(2.66%)
Day’s Range― - ―
52-Week Range$0.96 - $2.40
Previous CloseN/A
Volume1.21K
Average Volume (3M)706.00
Market Cap
$27.25M
Enterprise Value$18.57M
Total Cash (Recent Filing)$351.00K
Total Debt (Recent Filing)$645.00K
Price to Earnings (P/E)―
Beta-0.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,580,744
10 Day Avg. Volume209
30 Day Avg. Volume706
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)28.75
Price to Sales (P/S)43.17
P/FCF Ratio-7.94
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue21.61
Enterprise Value/Gross Profit-40.10
Enterprise Value/Ebitda-2.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth indicates improving commercialization after several years of near-zero sales. Sustained adoption could provide a foundation for operating leverage, although the company must still convert growth into viable margins and cash flow.
Improving Commercial TractionThe higher revenue base suggests the business is progressing beyond its historically limited commercialization stage. A larger recurring operating base could support future scale if product demand continues and costs are brought under control.
Limited Absolute DebtReported debt is modest in absolute dollars, which limits traditional interest and principal obligations compared with a heavily leveraged company. This provides some structural flexibility, though negative equity and funding needs materially weaken the benefit.
Bears Say
Severe UnprofitabilityLosses are exceptionally large relative to revenue, while negative gross profit shows the core economics are not yet viable. Without substantial cost reduction or pricing improvement, additional revenue may continue increasing activity without producing sustainable earnings.
Persistent Cash BurnOperating losses are translating directly into cash outflows, leaving the company dependent on external funding to sustain operations. Persistent burn reduces financial resilience and makes future growth more vulnerable to financing availability and dilution.
Negative Equity And Funding DependenceNegative equity and declining assets indicate a weakened balance sheet, while insider bridge financing demonstrates reliance on capital support. Convertible loan terms may increase future dilution and signal limited access to durable external funding.
Harvard Apparatus Regenerative Technology News
HRGN FAQ
What was Harvard Apparatus Regenerative Technology’s price range in the past 12 months?
Harvard Apparatus Regenerative Technology lowest stock price was $0.96 and its highest was $2.40 in the past 12 months.
What is Harvard Apparatus Regenerative Technology’s market cap?
Harvard Apparatus Regenerative Technology’s market cap is $27.25M.
When is Harvard Apparatus Regenerative Technology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Harvard Apparatus Regenerative Technology’s earnings last quarter?
Currently, no data Available
Is Harvard Apparatus Regenerative Technology overvalued?
According to Wall Street analysts Harvard Apparatus Regenerative Technology’s price is currently Overvalued.
Does Harvard Apparatus Regenerative Technology pay dividends?
Harvard Apparatus Regenerative Technology does not currently pay dividends.
What is Harvard Apparatus Regenerative Technology’s EPS estimate?
Harvard Apparatus Regenerative Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Harvard Apparatus Regenerative Technology have?
Harvard Apparatus Regenerative Technology has 17,580,744 shares outstanding.
What happened to Harvard Apparatus Regenerative Technology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Harvard Apparatus Regenerative Technology?
Currently, no hedge funds are holding shares in HRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Technical Analysis
Pluri
―
BioRestorative Therapies
―
Creative Medical Technology Holdings
―
Celularity
―
Longeveron
―